Emma Walmsley, GlaxoSmithKline CEO (Mandel Ngan/AFP via Getty Images)
April 28, 2021 11:27 AM EDTUpdated 11:43 AM
Pharma

The pres­sure builds for Em­ma Walm­s­ley as Glax­o­SmithK­line miss­es Q1 pro­jec­tion, drops more can­cer drugs

Nicole DeFeudis

Editor

Glax­o­SmithK­line CEO Em­ma Walm­s­ley is stay­ing fo­cused on the com­pa­ny’s split as earn­ings slide and El­liott Man­age­ment lurks on the side­lines, threat­en­ing to launch one …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

A service from the Financial Times